Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase.
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002470:Cell Survival / Q000187:drug effects; D004357:Drug Synergism; D007739:L Cells; D051379:Mice; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use
D058892:Adenosine Deaminase Inhibitors; D009700:Nucleoside Deaminases; D014740:Vidarabine; D000225:Adenine